Renalytix and Quest Diagnostics partner to expand kidneyintelX.dkd testing across the US
- nuaxia
- il y a 6 jours
- 1 min de lecture
Renalytix has signed a multi-year agreement with Quest Diagnostics to expand US access to its kidneyintelX.dkd blood test for patients with type 2 diabetes and chronic kidney disease.
The collaboration is designed to make kidneyintelX.dkd accessible through Quest's national diagnostics network, broadening physician access to a test that assesses risk of progressive kidney-function decline.
kidneyintelX.dkd is FDA-authorised and Medicare-reimbursed, supporting its use in identifying higher-risk patients who may benefit from earlier intervention and more intensive disease management.
Field | Content |
Alert Type | Industry Update |
Companies | Renalytix; Quest Diagnostics |
Agreement Type | Multi-year diagnostics collaboration |
Product | kidneyintelX.dkd |
Therapy Area | Chronic kidney disease; type 2 diabetes |
Technology or Modality | Blood-based prognostic diagnostic test |
Geography | United States |
What Happened | Renalytix signed a multi-year agreement with Quest Diagnostics to expand access to kidneyintelX.dkd through Quest's US diagnostics network. |
Why It Matters | Quest's national reach could materially increase physician and patient access to kidneyintelX.dkd. |
Supporting Context | The test is FDA-authorised and Medicare-reimbursed for assessing risk of progressive kidney-function decline in adults with type 2 diabetes and early-stage chronic kidney disease. |
Potential Impact | Broader access could support earlier risk stratification and more targeted intervention for patients at increased risk of kidney disease progression. |
Key Takeaway | Renalytix is partnering with Quest Diagnostics to expand US access to kidneyintelX.dkd. |
What to Watch | Commercial rollout through Quest and subsequent adoption by physicians and health systems. |
Primary Source | Renalytix |
Relevant Date | 1 September 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Commentaires